Fortrea Holdings (FTRE) Consolidated Net Income (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Consolidated Net Income came in at -$13.2 million in Q2 2026, up 44.07% on a QoQ basis from -$23.6 million in Q1 2026.
Analysis
Fortrea Holdings (FTRE) Consolidated Net Income (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 4 years of Consolidated Net Income data on file, last reported at -$13.2 million in Q2 2026.
- Quarterly Consolidated Net Income changed N/A year-over-year to -$13.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$36.8 million (down 1215.15% YoY) and the FY2024 annual result came in at -$57.0 million, down 976.92% from the prior year.
- Consolidated Net Income improved to -$13.2 million in Q2 2026, from -$23.6 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $66.4 million in Q2 2022 to a low of -$39.1 million in Q2 2024.
- A 4-year average of $2.0 million and a median of -$5.9 million in 2023 frame the typical range for Consolidated Net Income.
- The widest YoY moves for Consolidated Net Income: up 315.25% in 2024, down 774.14% in 2024.
- Tracing FTRE's Consolidated Net Income over 4 years: stood at -$13.6 million in 2022, then soared by 56.62% to -$5.9 million in 2023, then surged by 315.25% to $12.7 million in 2024, then sank by 203.94% to -$13.2 million in 2026.
- The last three Consolidated Net Income figures came in at -$13.2 million (Q2 2026), -$23.6 million (Q1 2026), and $12.7 million (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.21 Bn | 132.36 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.73 Bn | 58.55 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.59 Bn | 52.46 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.13 Bn | 35.04 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.55 Bn | 32.24 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.60 Bn | 27.77 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.70 Bn | 26.54 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Fortrea Holdings | 1.73 Bn | 1.56 Bn | 139.20 Mn | -13.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.20 Mn |
| Mar 31, 2026 | -23.60 Mn |
| Dec 31, 2025 | -32.50 Mn |
| Sep 30, 2025 | -15.90 Mn |
| Jun 30, 2025 | -374.90 Mn |
| Mar 31, 2025 | -562.90 Mn |
| Dec 31, 2024 | -61.20 Mn |
| Sep 30, 2024 | -27.90 Mn |
| Jun 30, 2024 | -138.40 Mn |
| Mar 31, 2024 | -101.00 Mn |
| Dec 31, 2023 | -54.50 Mn |
| Sep 30, 2023 | -14.00 Mn |
| Jun 30, 2023 | 30.80 Mn |
| Mar 31, 2023 | 12.50 Mn |
| Dec 31, 2022 | -13.60 Mn |
| Sep 30, 2022 | 60.60 Mn |
| Jun 30, 2022 | 66.40 Mn |